BIIB021
BIIB021 (CNF2024) is an orally active, fully synthetic inhibitor of HSP90 with a Ki and an EC50 of 1.7 nM and 38 nM, respectively[1].
Product Specifications
CAS Number
848695-25-0
Product Name Alternative
CNF2024
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Autophagy; HSP
Type
Reference compound
Related Pathways
Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/BIIB021.html
Purity
99.19
Solubility
DMSO : ≥ 45 mg/mL
Smiles
ClC1=C2C(N(C=N2)CC3=C(C(OC)=C(C=N3)C)C)=NC(N)=N1
Molecular Formula
C14H15ClN6O
Molecular Weight
318.76
Precautions
H302, H315, H319, H335
References & Citations
[1]Lundgren, Karen., et al. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Molecular Cancer Therapeutics (2009), 8 (4), 921-929.|[2]B?ll B, et al. Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity. Clin Cancer Res. 2009 Aug 15;15 (16) :5108-16.|[3]Yin X, et al. BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy. Int J Cancer. 2010 Mar 1;126 (5) :1216-25|[4]Zhang H, et al. BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance. Int J Cancer. 2010 Mar 1;126 (5) :1226-34
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
HSP90
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNUB2463-500 1x 500 µL
Ki-67 (Proliferating Cell Marker) (MKI67/2463), 0.2mg/mL
Sign In for Pricing
View Details